A new malaria vaccine could significantly reduce deaths after research has found it to be “safe and well tolerated”, new clinical trials have suggested.
The jab – known as RH5.1/Matrix-M – targets malaria in the “blood stage”, attacking the plasmodium falciparum parasite that causes the deadliest form of the disease passes through the liver.
